Hummingbird Bioscience, a precision biotherapeutics company discovering and developing biologic medicines for hard-to-treat diseases, appointed Angèle Maki, chief business officer.

Maki has two decades of experience in the biotech and pharma industry, with a track record of successful deals and partnerships across multiple therapeutic areas and modalities. Most recently, she served as senior vice president and head of business development at ReCode Therapeutics, where she led business development, corporate development, investor, and public relations. At ReCode Therapeutics, she was part of the team that raised a $120 million series B extension. Prior to ReCode, Maki held business development roles at Medarex followed by BMS, Genentech, Merck & Co, and Eli Lilly.

Piers Ingram, CEO, and co-founder of Hummingbird Bioscience said: “We are delighted that Angèle is joining our team. Her deep experience as a business development leader combined with her proven ability to execute on strategic transactions in biotech and pharma, makes her invaluable to our journey in bringing precision medicines to patients.”

“I am excited to join Piers, Jerome, and the Hummingbird Bio Board of Directors and investors in driving the mission of delivering precision therapeutics to patients with unmet need. I believe Hummingbird Bio’s approach to precision medicines and its promising clinical antibody assets will redefine the next generation of precision therapeutics,” said Maki.